Sai Life Sciences Releases FY26 Financial Results, Reporting Rs. 3,489.10 Million Profit and Rs. 36,261.40 Million Assets
Sai Life Sciences Limited today released its financial results for the year ended March 31, 2026, along with unaudited results for the quarter ended March 31, 2026. The company reported significant annual figures across both standalone and consolidated statements.The Board of Directors noted the audited financial results for the standalone and consolidated entities, alongside the corresponding results for the quarter ended March 31, 2026. The statutory auditors, M/s. Deloitte Haskins & Sells LLP, issued an unmodified opinion on the Annual Audited Standalone and Consolidated Financial Results for the fiscal year ended March 31, 2026.
Key Financial Performance Highlights (Year Ended 31 March 2026)
Sai Life Sciences reported total income of 22,416.20 million Rs. in its consolidated books for the year ended March 31, 2026, compared to 16,945.70 million Rs. in the previous fiscal year. The consolidated profit for the year reached 3,489.10 million Rs., resulting in an annual basic earnings per share (EPS) of 16.63.The standalone results mirrored this growth, posting total income of 21,532.26 million Rs. and a profit of 3,414.81 million Rs.
Comparative Financial Results (Rs. in million, except per share data)
| Metric | FY Ended 31 March 2026 | FY Ended 31 March 2025 |
|---|---|---|
| Consolidated Total Income | 22,416.20 | 16,945.70 |
| Consolidated Total Profit | 3,489.10 | 1,701.32 |
| Standalone Total Income | 21,532.26 | 16,420.48 |
| Standalone Total Profit | 3,414.81 | 1,734.62 |
| Basic Earnings Per Share (EPS) | 16.63 | 8.83 |
Standalone and Consolidated Balance Sheet Status
The Balance Sheet data for the year ended March 31, 2026, indicates substantial asset accumulation for the Group. The total consolidated assets stood at 36,261.40 million Rs., an increase from 31,599.75 million Rs. in the previous year.Consolidated Balance Sheet (As at 31 March 2026)
| Component | Amount (Rs. in million) |
|---|---|
| Total Assets | 36,261.40 |
| Non-Current Assets | 22,156.10 |
| Current Assets | 14,105.30 |
| Total Equity | 24,836.88 |
| Total Liabilities | 11,424.52 |
The company's current liabilities totaled 8,336.78 million Rs., reflecting strong financial structure compared to total assets.
Cash Flow Summary
The Statement of Cash Flows for the year ended March 31, 2026, highlights robust cash generation. The net cash generated from operating activities was 5,091.33 million Rs. The net cash used in investing activities was (3,954.11) million Rs., resulting in a positive net increase in cash and cash equivalents of 788.05 million Rs.Audit Conclusion
The statutory auditors confirmed that the Annual Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026, are presented in accordance with Indian Accounting Standards and provide a true and fair view of the Group’s financial position.SAILIFE Stock Price Movement
Sai Life Sciences Limited rallied strongly on Thursday, gaining 3.10% to settle at ₹1112.5, marking another upward move for the pharmaceutical stock. The equity was supported by robust trading volume of 1.25 million shares, pushing the price close to its 52-week high of ₹1139.4.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: